#USA #cancer therapy #San Francisco #Marathon Fusion #Terbium-149

Marathon Fusion Unveils New Production Method for Terbium-149

Marathon Fusion has recently announced a groundbreaking approach to produce Terbium-149 (Tb-149), a highly sought-after radioactive isotope for cancer treatment. This innovative method promises to meet the significant demand for Tb-149, which has long been hindered by limited supply and production capabilities.

The Promise of Terbium-149

Terbium-149 has been recognized in the medical community for decades as a key element in developing targeted cancer therapies. This radioactive isotope possesses a unique set of properties that make it particularly effective in radiotherapy, including its ability to emit alpha particles capable of damaging cancer cells while minimizing harm to surrounding healthy tissue. Furthermore, Tb-149 also delivers positron emissions that can facilitate imaging, allowing physicians to monitor tumor response during treatment.

However, despite its potential, the production of Tb-149 has been fraught with challenges. Historically, researchers have struggled with a supply bottleneck that has precluded the isotope's transition into clinical trials. Marathon Fusion's recent work aims to break down these barriers and create a sustainable pathway for Tb-149 production.

The Challenges with Current Production Methods

According to a 2025 study published in Europe, the limited availability of Tb-149 has been a critical factor preventing the isotope's entry into clinical trial stages. The current production methods are largely centralized, involving high costs and logistical obstacles due to the isotope's relatively short half-life of just over four hours. This presents dire constraints, especially when compared to other isotopes like molybdenum-99 or lutetium-177, which have longer half-lives and are more easily managed in centralized production scenarios.

A Revolutionary Approach

Marathon Fusion's new paper presents a unique solution using a precursor isotope, gadolinium-150 (Gd-150). By creating a more stable supply of Gd-150 and utilizing existing medical cyclotrons, the company aims to facilitate the onsite production of Tb-149, thereby mitigating the logistics issues associated with its short half-life.

In a parallel drawn to fluorine-18 production for PET imaging, Marathon’s proposed method allows Gd-150 to be produced centrally and then locally irradiated to generate Tb-149. Unlike the precursor used for fluorine-18, Gd-150 boasts a half-life of 1.8 million years, making it feasible to store and transport without significant losses.

Potential Impact on Cancer Treatment

This revelation could revolutionize the landscape of cancer treatment by enabling a consistent and sufficient supply of Tb-149. Adam Rutkowski, CTO and Co-founder of Marathon Fusion, emphasized the urgency of this development, stating, "We've been waiting for a practical solution that leverages existing infrastructure to push Tb-149 drugs through clinical trials and ultimately increase patient access worldwide."

The production of Gd-150 is expected to harness abundant isotopes like europium-151, which can be irradiated to support the substantial demand for Tb-149. Marathon Fusion anticipates the ability to produce enough Gd-150 annually to meet the needs of tens of thousands of Tb-149 doses, addressing a long-standing gap in the market.

The Future of Radiotherapy and Fusion Technology

Looking ahead, the potential synergies between emerging nuclear fusion technologies and isotope production present a thrilling landscape for medical advancements. While numerous companies aim to develop practical fusion power plants by the 2030s, the isotopes produced through fusion reactors may soon provide an alternative source for radiotherapy, paving the way for new treatment options.

Dr. Jason Parisi, Principal Research Scientist at Marathon Fusion, emphasized the importance of experimental validation for this method. "If proven successful, this could signify a monumental step in solving the supply issues surrounding Tb-149, enabling its clinical use sooner rather than later."

Marathon Fusion stands at the forefront of isotope production technology, seeking to not only ensure a steady supply of crucial medical isotopes but also streamline the process of delivering effective cancer treatments globally. By harnessing existing infrastructures and invoking innovative production methodologies, Marathon is positioned to redefine the future of cancer therapy.

For further details on this pivotal advancement in isotope production and potential implications for the medical field, visit Marathon Fusion's website.